Online inquiry

IVTScrip™ mRNA-Anti-CD4, BT-061(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4821MR)

This product GTTS-WQ4821MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD4 gene. The antibody can be applied in Psoriasis, Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000616.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 920
UniProt ID P01730
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD4, BT-061(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ4821MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11802MR IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MK-3475
GTTS-WQ10154MR IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA LBR-101
GTTS-WQ15444MR IVTScrip™ mRNA-Anti-ERBB3, U3-1287(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA U3-1287
GTTS-WQ522MR IVTScrip™ mRNA-Anti-CD40, 4D11(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 4D11
GTTS-WQ10225MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LFB-R593
GTTS-WQ2113MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Alb-IFNA2 R23 (608)
GTTS-WQ2738MR IVTScrip™ mRNA-Anti-IL23A, AMG-139(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG-139
GTTS-WQ7654MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN-1029(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GEN-1029
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW